Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06732596 · ClinicalTrials.gov registry record · NA
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
A NA study of Opioid Use Disorder, sponsored by Boston Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06732596: Recruiting NA study of Opioid Use Disorder, sponsored by Boston Medical Center.
NCT06732596 is a NA study of Opioid Use Disorder that is actively recruiting participants, run by Boston Medical Center. The registered enrollment target is 100 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06732596, a NA study of Opioid Use Disorder, is actively recruiting participants, sponsored by Boston Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention. The intervention involves an Embodied Conversational Agent (ECA), a virtual, animated computer agent designed to simulate natural face-to-face conversations. ECAs have been shown to help individuals manage their healthcare in other settings, and this study seeks to evaluate their potential in supporting patients on medication for opioid use disorder (MOUD).
Primary Outcome
Engaged in buprenorphine treatment or treatment retention is defined as a participant's treatment period of at least 365 days, including those with multiple disengagement and reengagement periods, as long as any gap in active prescriptions or receipt of injections is less than 60 days.
Conditions Studied
Interventions
- OTHER Embodied conversational agent (ECA)
- OTHER Technical support
- OTHER Additional ECA messages
- OTHER Additional incentives
Study Locations (1)
Massachusetts
- Office-Based Addiction Treatment (OBAT) Clinic, BMC - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT06732596 shows while recruiting
NCT06732596 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 4 interventions - of which Embodied conversational agent (ECA) is the first listed.
NCT06732596 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06732596 about?
NCT06732596 is a clinical study titled "Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents". This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention. The intervention involves an Embodied Conversational Agent (ECA), a virtual, animated computer agent designed to simula...
What is the current status of trial NCT06732596?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-10-30. Estimated completion is 2026-12.
What conditions does trial NCT06732596 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT06732596?
The interventions under investigation include: Embodied conversational agent (ECA) (OTHER), Technical support (OTHER), Additional ECA messages (OTHER), Additional incentives (OTHER).
Who is sponsoring clinical trial NCT06732596?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06732596 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06732596's enrollment target sits among peer trials
100 130th of 257 higher than 121 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
Using Facebook to Support Opioid Recovery Among American Indian Women
RECRUITING · NA
-
Pilot Testing a Novel Remotely Delivered Intensive Outpatient Program for Individuals With OUD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01773278 · 100 participants · Phase 2
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI